Pharmacogenomics to Revive Drug Development in Cardiovascular Disease

被引：0
作者：
Marie-Pierre Dubé
Simon de Denus
Jean-Claude Tardif
机构：
[1] Montreal Heart Institute,Faculty of Medicine
[2] Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre,Faculty of Pharmacy
[3] Université de Montréal,undefined
[4] Université de Montréal,undefined
来源：
Cardiovascular Drugs and Therapy | 2016年 / 30卷
关键词：
Cardiovascular; Drug discovery; Pharmacogenomics; Personalized medicine; Mendelian randomization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Investment in cardiovascular drug development is on the decline as large cardiovascular outcomes trials require considerable investments in time, efforts and financial resources. Pharmacogenomics has the potential to help revive the cardiovascular drug development pipeline by providing new and better drug targets at an earlier stage and by enabling more efficient outcomes trials. This article will review some of the recent developments highlighting the value of pharmacogenomics for drug development. We discuss how genetic biomarkers can enable the conduct of more efficient clinical outcomes trials by enriching patient populations for good responders to the medication. In addition, we assess past drug development programs which support the added value of selecting drug targets that have established genetic evidence supporting the targeted mechanism of disease. Finally, we discuss how pharmacogenomics can provide valuable evidence linking a drug target to clinically relevant outcomes, enabling novel drug discovery and drug repositioning opportunities.
引用
收藏
页码：59 / 64
页数：5
相关论文
共 150 条
[1]  
Mozaffarian D(2015)Heart disease and stroke statistics—2015 update: a report from the American heart association Circulation 131 e29-322
[2]  
Benjamin EJ(2011)The productivity crisis in pharmaceutical R&D Nat Rev Drug Discov 10 428-38
[3]  
Go AS(2014)SCientific and regulatory reasons for delay and denial of fda approval of initial applications for new drugs, 2000–2012 JAMA 311 378-84
[4]  
Arnett DK(2015)Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol 65 1567-82
[5]  
Blaha MJ(2012)Biomarkers and surrogate endpoints in clinical trials Stat Med 31 2973-84
[6]  
Cushman M(2014)High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm Clin Pharmacol Ther 96 48-56
[7]  
Pammolli F(2012)Proteomics investigations of HDL: challenges and promise Curr Vasc Pharmacol 10 410-21
[8]  
Magazzini L(2011)Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 127-35
[9]  
Riccaboni M(2015)HDL and cardiovascular risk: is cholesterol in particle subclasses relevant? Eur Heart J 36 10-2
[10]  
Sacks LV(1996)Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 605-13
12345678910